4.5 Article

NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines

Journal

Publisher

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2017.0003

Keywords

-

Categories

Funding

  1. Astellas
  2. AstraZeneca
  3. Celldex Therapeutics
  4. Clovis Oncology
  5. Genomic Health, Inc.
  6. Kyowa Hakko Kirin
  7. Jazz Pharmaceuticals
  8. Novartis Pharmaceuticals Corporation
  9. NOVOCURE
  10. independent educational grant from Merck Co., Inc.

Ask authors/readers for more resources

The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available